Abbott Introduces Canada's First Remote Neuromodulation Patient-Care Technology, NeuroSphere Virtual Clinic, to Treat People with Chronic Pain and Movement Disorders*

  • The new system allows patients implanted with an Abbott neuromodulation device to communicate with their physician and remotely receive treatment in real time, regardless of location §

Abbott (NYSE: ABT) announces the Health Canada licencing† of NeuroSphere™ Virtual Clinic, a remote programming technology that is the first of its kind in Canada and is compatible with Abbott's suite of neuromodulation technologies. NeuroSphere Virtual Clinic has the potential to increase access to optimal treatment for patients living with chronic pain, Parkinson's disease, or essential tremors who might otherwise have difficulty receiving care from their healthcare provider due to location or being unable to travel to seek care.

Sample screen view of a patient-physician interaction on Abbott's NeuroSphere Virtual Clinic

Abbott's NeuroSphere Virtual Clinic gives patients the flexibility and comfort of receiving care anywhere § by connecting with their doctor via secure in-app video chat and an integrated remote programming feature. This feature enables clinicians to prescribe new treatment settings remotely to the patient's neurostimulation device using the clinician programmer app and a new, simple, and secure remote care connection.

In Canada , it is estimated that more than 6 million people live with chronic pain, 1 almost 100,000 people live with Parkinson's disease, 2 and almost 2 million people live with an essential tremor. 3 , 4 Many of these people who don't live close to a healthcare centre have difficulty accessing care due to the inability to see their doctor in-person. They are often challenged by the time associated with the trip, and/or the availability of a caregiver to help with their travel. In addition to the time implications, patients and caregivers may experience considerable travel-related costs and reduced employment wages. This is particularly true for those living in rural, northern, and remote parts of the country. 5

"Without alternatives to in-person programming, many of these patients may delay or forego care, particularly those who face a travel burden," said Alfonso Fasano , M.D., Ph.D., with Krembil Brain Institute at Toronto Western Hospital, part of the University Health Network. "Fortunately, innovative virtual healthcare options are changing the treatment landscape, ultimately extending care beyond clinic walls. Remote programming is an important new option that allows patients to communicate with their physicians virtually to ensure proper device settings and functionality. This brings the convenience of connected care to neurostimulation therapy, giving patients the ability to manage their therapy in a way that fits their personal needs."

NeuroSphere Virtual Clinic is compatible with the following Canadian-licensed Abbott neuromodulation devices: **

  • Proclaim™ spinal cord stimulation (SCS), for the management of chronic, intractable pain of the trunk and/or limbs
  • Proclaim dorsal root ganglion (DRG) therapy, for the management of moderate to severe chronic intractable pain of the lower limbs
  • Infinity™ deep brain stimulation (DBS) therapy, for the management of Parkinson's disease and tremor

"For more than a decade, Abbott has been evaluating the treatment hurdles neuromodulation patients faced," said Pedro Malha, vice president, neuromodulation, Abbott. "During this time, we have diligently worked to find better ways of connecting patients to their doctors. The launch of NeuroSphere Virtual Clinic in Canada exemplifies Abbott's ability to put science and innovation to work, delivering solutions to help people live their best lives."

The ongoing evolution of Abbott neuromodulation technologies highlights the commitment to patient-centered research integrated with cutting-edge technologies to go beyond physical symptom relief and improve the lives of people with neurological disorders. Abbott's NeuroSphere Virtual Clinic was first launched in the United States in March 2021 .

*Neurostimulation systems for DBS are used in patients with levodopa-responsive Parkinson's disease or tremor. Please refer to the device Instructions for Use for details.

§ Anywhere with a cellular or Wi-Fi connection and sufficiently charged patient controller.

†The St. Jude Medical Clinician Programmer App and St. Jude Medical Patient Controller App used with the NeuroSphere Virtual Clinic are currently licensed.

**Certain configurations of the devices within may not have been licensed in accordance with Canadian law. Contact your local sales representative for the regulatory status of the device(s) in Canada . This product is intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events as applicable to Canada .

About Neuromodulation  
Neuromodulation is an advanced personalized treatment option often recommended for patients who suffer from chronic pain and certain movement disorders, such as Parkinson's disease and essential tremors. Abbott neuromodulation systems use a recharge-free implanted generator, and a thin wire called a lead to send mild electrical pulses to areas of the brain that cause pain or tremors. These pulses interrupt the signals responsible for these symptoms. 6

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

1 Prevalence of chronic pain among individuals with neurological conditions. Statistics Canada . Updated March 21, 2018 . Accessed on May 25, 2022 . https://www150.statcan.gc.ca/n1/pub/82-003-x/2018003/article/54921-eng.htm
2 About Parkinson's Disease. Parkinson's Canada . Accessed on May 25, 2022 . https://www.parkinson.ca/about-parkinsons/
3 Agarwal, S. (2020, July 14 ). Essential Tremor. Access on May 25, 2022 . https://www.ncbi.nlm.nih.gov/books/NBK499986/
4 Canada's population estimates: Age and sex, July 1, 2021 . Statistics Canada . Updated September 29, 2022 . Accessed May 25, 2022 . https://www150.statcan.gc.ca/n1/daily-quotidien/210929/dq210929d-eng.htm
5 Publicly funded medical travel subsidy programs in Canada . Canadian Social Work Review. Volume 34, Number 1, 2017, p. 123–139. Accessed May 24, 2022 . https://www.erudit.org/en/journals/cswr/1900-v1-n1-cswr03182/1040998ar/
6 Yu, H., & Neimat, J. (2008). The treatment of movement disorders by deep brain stimulation. Neurotherapeutics , 5, 26-36 https://dx.doi.org/10.1016/j.nurt.2007.10.072 .

Abbott Logo (PRNewsFoto/Abbott)

SOURCE Abbott

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/July2022/26/c0548.html

News Provided by Canada Newswire via QuoteMedia

ABT
The Conversation (0)
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative

  • New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trials
  • Abbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovation
  • The new programs build on a successful first year of the multi-million-dollar corporate initiative

Abbott (NYSE: ABT) today announced a series of new programs within its multi-million-dollar initiative to increase diversity in clinical trials and improve care among under-represented populations. The new additions to Abbott's Diversity in Clinical Trials initiative build on the partnerships, scholarships, and the focus on diversified participants in the company's own clinical trials during the initiative's first year.

The latest programs include the launch of a new initiative with the Norton Healthcare Foundation to build and implement new models of sustainable clinical research alongside the Institute for Health Equity, a Part of Norton Healthcare in Louisville, Ky. ; a new training program for clinical research coordinators in partnership with Barnett International; and a newly-created Diversity in Research Office at Abbott focused on ensuring diverse representation in clinical trials.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
richard murray md

Avisa Diagnostics Appoints Dr. Richard Murray as Chief Medical Officer

Avisa Diagnostics Inc. (CSE:AVBT) (Avisa), a clinical-stage medical device company developing an ultra-rapid, point-of-care biomarker breath test for the detection and monitoring of virulent bacterial lung infections, is pleased to announce that the Company has hired Richard K. Murray, M.D., to the newly created position of Chief Medical Officer (CMO).

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally. Prior to his industry career, he was a practicing physician in cardiovascular-pulmonary medicine and an asthma researcher at the Hospital of the University of Pennsylvania. Dr. Murray has an M.D. from Howard University and an M.A. in Chemistry and A.B. in Psychology from Clark University. Dr. Murray currently is Board Chair of the Asthma and Allergy Foundation of America.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×